Skip to main content
Clinical Trials/NCT06708507
NCT06708507
Recruiting
Not Applicable

A Prospective Study on the Correlation Between Tissue-resident Immune Cell Subsets and Graft-versus-host Disease Following Hematopoietic Stem Cell Transplantation.

Nanfang Hospital, Southern Medical University1 site in 1 country40 target enrollmentNovember 16, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Graft-versus-Host Disease
Sponsor
Nanfang Hospital, Southern Medical University
Enrollment
40
Locations
1
Primary Endpoint
Association between tissue-resident Immune cell subsets in organ and acute graft-vs-host disease (aGVHD) outcomes.
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This is a prospective study investigating the role of tissue-resident immune cell subsets in the occurrence and progression of graft-versus-host disease following hematopoietic stem cell transplantation. Approximately 40 subjects(including 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients ).

Detailed Description

This study was a single-center, observational, prospective cohort study. The study lasted for 3 months, from 2024.11 to 2025.02.It is planned to enroll 40 subjects, divided into 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients. No randomization or any protocol-driven treatment will be performed or provided to subjects during the course of the study. Treatment decisions and selection of treatment options are left to the discretion of the treating physician, if clinically appropriate. All recipients will be followed for aGVHD evaluation,overall survival(OS) ,disease-free survival (DFS). aGVHD were graded according to published guidelines. All recipients will be monitored every month until the study is completed.

Registry
clinicaltrials.gov
Start Date
November 16, 2024
End Date
May 31, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Voluntarily sign the informed consent form;
  • Age 16-65 years old
  • Clinically diagnosed with GVHD for the first time/receiving GVHD treatment.

Exclusion Criteria

  • Have a history of other tumors
  • With poor compliance or mental disorders
  • Infected with HIV and HCV
  • With uncontrolled HBV infection
  • With other autoimmune diseases
  • Those who are judged by the researcher to be unsuitable to participate in this study

Outcomes

Primary Outcomes

Association between tissue-resident Immune cell subsets in organ and acute graft-vs-host disease (aGVHD) outcomes.

Time Frame: 100days

Measure the number/proportion of resident T,B and macrophage cell subsets in the main organ of aGVHD(skin,intestine and liver).

Secondary Outcomes

  • Association between tissue-resident Immune cell subsets in organ and overall survival(OS).(100days)
  • Association between tissue-resident Immune cell subsets in organ and disease-free survival (DFS)(100days)

Study Sites (1)

Loading locations...

Similar Trials